Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
82.73 EUR | +1.15% | +4.09% | +19.52% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 33.77 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+19.52% | 54.1B | - | ||
+11.91% | 227B | B | ||
+15.46% | 198B | B- | ||
+18.58% | 142B | B- | ||
+30.36% | 111B | A- | ||
+0.65% | 64.16B | A- | ||
+5.82% | 51.41B | B+ | ||
+11.23% | 45.32B | A | ||
+5.73% | 37.32B | - | ||
+27.16% | 32.13B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- EW Stock
- EWL Stock
- Ratings Edwards Lifesciences Corporation